---
layout: post
title: "Notice of the Denial of a Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)"
date: 2026-02-05 19:08:32 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-04735
original_published: 2024-03-06 00:00:00 +0000
significance: 8.00
---

# Notice of the Denial of a Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 06, 2024 00:00 UTC
**Document Number:** 2024-04735

## Summary

The Food and Drug Administration (FDA or the Agency) is announcing the availability of the decision to deny a request for a hearing regarding the proposal of the Center for Drug Evaluation and Research (CDER) to refuse to approve the supplemental new drug application (sNDA) 205677-004, submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), for the treatment of jet lag disorder. The decision, which also refuses approval of sNDA 205677-004, is available in the docket identified by the number in the heading of this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/06/2024-04735/notice-of-the-denial-of-a-hearing-request-regarding-a-proposal-to-refuse-to-approve-a-supplemental)
- API: https://www.federalregister.gov/api/v1/documents/2024-04735

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
